PatriotBioBull

Patriot 🇺🇸 | Entertain & inspire with truth + satire 😉 | Bullish on $IBRX → ANKTIVA revolutionizing cancer immunity | 700% revenue rocket | Global approvals

[PatriotBioBull @Anvil001]

🌍 Global domination alert! ImmunityBio’s ANKTIVA® now cleared in 33 countries across US, UK, EU & Saudi Arabia. First immunotherapy EVER approved in Europe for BCG-unresponsive NMIBC.
Patient access exploding = revenue potential exploding!
$IBRX
#IBRX #Anktiva #CancerTreatment

[Bullish @bullishbruk]

To all my fellow $IBRX longs — stay strong and keep the faith.
Not long ago, we endured relentless shorting that hammered the stock all the way down to $1.90. We held through the fear, the doubt, and the noise.
Now in early June 2026, the shorts are pulling the exact same playbook they ran in early January…desperate attacks, trying to shake weak hands one last time.
But this time feels different because the foundation is so much stronger.
Just wait until the Q2 report drops. The numbers, the progress, the momentum….IMO, we’re going to be singing a completely different tune.
I’m staying long and strong all the way to my price target of $80+. This is the same conviction that got us through the $1.90 days. The shorts are running out of time and ammunition.
We’ve been here before… and we know how this story ends.
$IBRX is strong. ANKTIVA Army — hold the line. 💎🙌
Disclaimer: This is not financial advice. I am not a financial advisor. Always do your own due diligence and research before making any investment decisions. Stock prices can go up or down, and past performance is not indicative of future results.

[Lori Mills @LoriMills4CA42]

On our way to meet with Senator Ron Johnsons team. Unleash #ANKTIVA @bullishbruk

[Lori Mills @LoriMills4CA42]

Andrew and I are in Washington, D.C. today, where I had the honor of testifying before the FDA on behalf of cancer patients everywhere.
We’re fighting to bring #ANKTIVA and natural killer (NK) cell therapies into the spotlight, giving hope and new options to those who need them most.
Please watch the testimony. I hope it resonates with you.
Together, we’re pushing for real progress. @bullishbruk
@DrPatrick

[Bullish @bullishbruk]

ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors - https://t.co/a1Bcxe7qyn $IBRX https://t.co/xAA2Fhohkk

[Bullish @bullishbruk]

$IBRX Dr. Aswin, you are on point!
I agree with the oncologist—medicine must rest on rigorous evidence, not just early enthusiasm, and IL-15 superagonists like ANKTIVA represent a genuinely exciting shift toward immune activation. Promising signals need validation.
That said, since safety has been proven and late-stage cancer patients don’t have another 10 years to wait, why not approve ANKTIVA now? We can use RWE to supplement trial data and closely follow progress in real time, striking the right balance between protecting patients and giving those with no options a fighting chance today. @LoriMills4CA42 @DrPatrick @FDA_KyleD

[Dr. Pat Soon-Shiong @DrPatrick]

Had a great discussion with @AfricaCDC and @MWayengera. Clinicians and scientists must come together to resolve this crisis. Discussing this with @ChrisCuomo today. Africa CDC is taking leadership in addressing Ebola crisis as urgently as they can. Agree this is what is called leadership.

[Dr. Pat Soon-Shiong @DrPatrick]

On with @ChrisCuomo soon. @AfricaCDC Leadership under Dr. Jean Kaseya is being highly proactive both in Congo and Uganda to address this crisis and patients with severe illness. Will discuss a universal finding of immune collapse with ebola and sepsis. @NewsNation

[Dr. Pat Soon-Shiong @DrPatrick]

Connecting the scientific dots. Please note that we are in the planning clinical trial stages to address lymphopenia and it IS NOT APPROVED as a therapy. IL-15 is the molecule we are discussing here. So connecting the dots:

1. 2007 workshop by NCI ranking IL15 as the number one ranked molecule since it is a T CELL GROWTH FACTOR.
https://t.co/Yxc6bAje0f

2. When you age, or when you have infection or cancer your T cells decrease, sometimes to dangerous levels... that’s called lymphopenia.

3. The diagnosis of lymphopenia is EASILY made with a routine blood test performed millions of times everywhere in the world with what is called a CBC differential and the measurement is the “Absolute Lymphocyte count” or ALC

4. Zidar et al., 2019 (JAMA) including authors from Cleveland Clinic, Duke, Case Western reported that 20% suffer from Lymphopenia. Worse, these authors showed ~2x higher probably of dying earlier when you have severe lymphopenia... dying from what they report as “all causes” https://t.co/P8RVsZXJSK

5. Today I receive a paper in press 28 May 2026 entitled "First-week absolute lymphocyte count dynamics and 28-day mortality in older adults with sepsis".

The author's stated, "Sepsis is now understood not only as hyper inflammation but also as a state of prolonged immunosuppression."

https://t.co/S8zw9kwHbl

Amazing and timely paper.
I do not know these authors but I look forward to meeting them. It seems that doctors in Turkey get it and clinical trials are needed to confirm that treating lymphopenia could reduce mortality.

6. I must emphasize that to date, there is NO drug approved to treat lymphopenia and our goal is to initiate clinical trials to confirm the hypothesis that by treating lymphopenia we have the potential to improve mortality in patients with sepsis. The results of increased mortality in the findings reported in today's paper are striking.

Imagine the cost savings if we could reduce the ICU and hospital length of stay. Table 6 shows 10 days more in the ICU with lymphopenia and 12 days more in the hospital with significant increase of death in Figure 3

[Lori Mills @LoriMills4CA42]

Update- I will be flying to DC to testify to the FDA! Testimony Thursday! Pray!

[Bullish @bullishbruk]

$IBRX ANKTIVA — a wonder drug that has yet to be discovered for its full potential. @JTLonsdale @LoriMills4CA42

[Dr. Pat Soon-Shiong @DrPatrick]

So here’s a clue
From Nanobodies to Nantibodies.
The goal: ADCC and ADCP
I know that’s a foreign language but I’m sure many will figure that out..the future of antibody targeting

[Bullish @bullishbruk]

$IBRX agree wholeheartedly! SOON OR EVER! @DrPatrick @FDA_KyleD

[Dr. Pat Soon-Shiong @DrPatrick]

So what is next on the NantWorks platform as we emerge from 15 years of stealth. Remember Diabetes? Remember Abraxane..albumin bound paclitaxel. Well imagine Albumin linked GLIP-1 at one tenth of the dose? This is the program now nearing completion at Nantworks and trials completed ex -USA. Will share news over the next 6 months

[Robert Lufkin MD @robertlufkinmd]

In 2024 the FDA approved a drug for bladder cancer. It is now the most interesting molecule in longevity medicine that no one is talking about. (1/9)

[Dr. Pat Soon-Shiong @DrPatrick]

Here's the Lynch syndrome paper from NCI.

The trial is supported by the Cancer Prevention—Clinical Trials Network (CP-CTNet), a grant-funded network from the National Cancer Institute’s (NCI) Division of Cancer Prevention (DCP) that performs early-phase cancer prevention clinical trials. This trial represents the first cross-network trial performed by all five grant recipients and their affiliated organizations, at a total of 16 study sites.

As stated by the authors:

"Our trial employs a vaccination strategy that addresses common reasons for vaccine failure by targeting multiple antigens, using a proven adenoviral delivery system, and studying an immune-competent high-risk population without active cancer."

https://t.co/W3J4OMKNeo

[Dr. Pat Soon-Shiong @DrPatrick]

NANT Leonardo landed in California and cleared customs! Assembly begins next week of the world's first AI driven cell manufacturing robot.

[Gene @genejchan]

I love it when noobs value hypergrowth companies using backwards-looking numbers

$IONQ is guiding $265M organic rev, and will probably do close to $1B/year once $SKYT is included

They expect to continue 100%+ organic CAGR

This is our competition fam 🤣🤡

[Macro Ghost on Youtube @Deepvalue69420]

$IBRX HUGE Lung Cancer Breakthrough: ANKTIVA Phase 3 Results (34.7 vs 20.2 Months)
https://t.co/7YOWcHi86A
$NSCLC $ANKTIVA $CANCER

[Steve Grasso @grassosteve]

$INFQ

[Macro Ghost on Youtube @Deepvalue69420]

True $ibrx

Russell ranks all U.S. stocks by market capitalization (share price × number of shares). They draw a line: Top ~1,000 = Large-cap (Russell 1000). Next ~2,000 = Mid-cap (Russell Midcap). Kek!

$Immunitybio recently hit ~$8 billion market cap → it crossed the size threshold to qualify as a mid-cap stock. Russell does the big annual rebalance in June. Stocks that meet the criteria get added (or removed) around then.

This creates “forced buying” because index-tracking funds must buy the stock to match the index.